Harpoon_logo (002).jpg
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
June 04, 2021 16:00 ET | Harpoon Therapeutics
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting
May 19, 2021 17:02 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced...
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
September 21, 2020 07:00 ET | Precision Biosciences
DURHAM, N.C. and STAMFORD, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene...
Harpoon_logo (002).jpg
Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
April 27, 2020 06:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
November 21, 2019 04:00 ET | Harpoon Therapeutics; AbbVie Inc.
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration...
 Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
November 06, 2019 19:37 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will...
Poseida Therapeutics Raises $142 Million in Series C Financing
April 22, 2019 07:00 ET | Poseida Therapeutics, Inc.
SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer
July 20, 2018 10:30 ET | Poseida Therapeutics, Inc.
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving...
logo long.jpg
Significant Number of B-cell Maturation Antigen (BCMA) Targeted Therapies in Pipeline is Expected to Boost Market Growth
October 26, 2017 10:00 ET | Coherent Market Insights
SEATTLE, Oct. 26, 2017 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market (By product type: CAR-T cell, bispecific...
Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference
April 25, 2016 08:30 ET | Triumvira Immunologics Inc.
HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a...